Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Yan‐Jun Xiang"'
Autor:
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Jin-Kai Feng, Zong-Han Liu, Yun-Feng Shan, Yi-Tao Zheng, Qian-Zhi Ni, Shu-Qun Cheng
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background The use of Anti-PD-1 therapy has yielded promising outcomes in hepatocellular carcinoma (HCC). However, limited research has been conducted on the overall survival (OS) of patients with varying tumor responses and treatment durati
Externí odkaz:
https://doaj.org/article/28580eb814714c9bace2a2194c6774a8
Autor:
Hong-Fei Zhu, Jin-Kai Feng, Yan-Jun Xiang, Kang Wang, Li-Ping Zhou, Zong-Han Liu, Yu-Qiang Cheng, Jie Shi, Wei-Xing Guo, Shu-Qun Cheng
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of hepatocellular carcinoma (HCC). However, long-term survival outcomes and treatment response of HCC patients undergoing immunotherapy is unpredictable. The st
Externí odkaz:
https://doaj.org/article/3160f3deecbb447c921380c2af319223
Autor:
Wei‐Jun Wang, Zong‐Han Liu, Kang Wang, Hong‐Ming Yu, Yu‐Qiang Cheng, Yan‐Jun Xiang, Jin‐Kai Feng, Li‐Ping Zhou, Hong‐Kun Zhou, Wei‐Wei Pan, Wei‐Xing Guo, Jie Shi, Shu‐Qun Cheng
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11513-11524 (2023)
Abstract Background There is no consensus on the optimal regimen for unresectable recurrent hepatocellular carcinoma (HCC), so this retrospective study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with
Externí odkaz:
https://doaj.org/article/6862c0cf51ad41c4a4df7fb2b3c55385
Autor:
Zong‐Han Liu, Zong‐Tao Chai, Jin‐Kai Feng, Yu‐Chao Hou, Xiu‐Ping Zhang, Zhen‐Hua Chen, Yan‐Jun Xiang, Wei‐Xing Guo, Jie Shi, Shu‐Qun Cheng
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10294-10302 (2023)
Abstract Background Early and late recurrence of hepatocellular carcinoma (HCC) have different clinical outcomes, especially for those accompanied by microvascular invasion (MVI), but the definition of early recurrence remains controversial. Therefor
Externí odkaz:
https://doaj.org/article/ecc77391e83c454b8fa8ab123bd7951a
Autor:
Yu Jiang Master of Engineering, Kang Wang Master of Medicine, Yu-Ran Wang Master of Engineering, Yan-Jun Xiang Master of Medicine, Zong-Han Liu Doctor of Medicine, Jin-Kai Feng Doctor of Medicine, Shu-Qun Cheng Doctor of Medicine
Publikováno v:
Technology in Cancer Research & Treatment, Vol 22 (2023)
Microvascular invasion of hepatocellular carcinoma is an important factor affecting tumor recurrence after liver resection and liver transplantation. There are many ways to classify microvascular invasion, however, an international consensus is urgen
Externí odkaz:
https://doaj.org/article/002b7237f3444673bdd0ff161cb088e0
Autor:
Yu-Qing Zhang, Kang Wang, Jin-Kai Feng, Lu-Yun Yuan, Chao Liang, Yan-Jun Xiang, Xu Wang, Fei-Fei Mao, Shu-Qun Cheng
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundImmune checkpoint inhibitor (ICI), coupled with systemic chemotherapy, may enhance the clinical benefit of cancer by potentiating antitumor immunity, but its efficacy and safety are not clear in advanced intrahepatic cholangiocarcinoma (ICC
Externí odkaz:
https://doaj.org/article/20b04a6fc4454921a38cfb6e07a02fb1
Autor:
Kang Wang, Zong-Han Liu, Hong-Ming Yu, Yu-Qiang Cheng, Yan-Jun Xiang, Jing-Ya Zhong, Qian-Zhi Ni, Li-Ping Zhou, Chao Liang, Hong-Kun Zhou, Wei-Wei Pan, Wei-Xing Guo, Jie Shi, Shu-Qun Cheng
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Anti-programmed cell death ligand 1/vascular endothelial growth factor inhibition, coupled with chemotherapy, may potentiate antitumor immunity leading to enhanced clinical benefit, but it has not been investigated in advanced biliary tra
Externí odkaz:
https://doaj.org/article/7ddc1949430f42c7b30f2a22cd31a782
Autor:
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Jing-Ya Zhong, Shuang Feng, Qian-Zhi Ni, Hong-Fei Zhu, Wei-Wei Pan, Jing-Jing Li, Chao Liang, Hong-Kun Zhou, Yan Meng, Wan Yee Lau, Shu-Qun Cheng
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Background and aimsThe efficacy and safety of systemic atezolizumab and bevacizumab (atezo/bev) in treatment of patients with unresectable hepatocellular carcinoma (HCC) have been demonstrated. However, the efficacy of this treatment in patients with
Externí odkaz:
https://doaj.org/article/d03d269f9724481fb5da843f4f3ccb18
Autor:
Jie Shi, Kang Wang, Shuang Feng, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jian Zhai, Shu-Qun Cheng
Publikováno v:
BMJ Open, Vol 12, Iss 12 (2022)
Introduction Vascular invasion and metastasis are poor prognostic factors in patients with hepatocellular carcinoma (HCC). The efficacy of available therapeutic regimens for unresectable HCC is not satisfactory in HCC with portal vein tumour thrombos
Externí odkaz:
https://doaj.org/article/b37e661c87e54c3c98444de80e3044c6
Autor:
Jin-Kai Feng, Zong-Han Liu, Zhi-Gang Fu, Zong-Tao Chai, Ju-Xian Sun, Kang Wang, Yu-Qiang Cheng, Hong-Fei Zhu, Yan-Jun Xiang, Li-Ping Zhou, Jie Shi, Wei-Xing Guo, Jian Zhai, Shu-Qun Cheng
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposeThis study aimed to assess the efficacy and safety of a triple therapy that comprises transarterial chemoembolization (TACE), antiangiogenic-targeted therapy, and programmed death-1 (PD-1) inhibitors in a real-world cohort of patients with unr
Externí odkaz:
https://doaj.org/article/8a725b6662e54cd288062e6f0190f9c0